Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy.

Gupta D, Kumar M, Tyagi P, Kapoor S, Tyagi A, Barman TK, Kharbanda S, Kufe D, Singh H.

Nanomedicine. 2018 Apr 8. pii: S1549-9634(18)30073-X. doi: 10.1016/j.nano.2018.03.010. [Epub ahead of print]

PMID:
29641982
2.

High human herpesvirus 6 viral load in pediatric allogeneic hematopoietic stem cell transplant patients is associated with detection in end organs and high mortality.

Winestone LE, Punn R, Tamaresis JS, Buckingham J, Pinsky BA, Waggoner JJ, Kharbanda S.

Pediatr Transplant. 2018 Mar;22(2). doi: 10.1111/petr.13084. Epub 2017 Nov 27.

PMID:
29181879
3.

Numerous uncharacterized and highly divergent microbes which colonize humans are revealed by circulating cell-free DNA.

Kowarsky M, Camunas-Soler J, Kertesz M, De Vlaminck I, Koh W, Pan W, Martin L, Neff NF, Okamoto J, Wong RJ, Kharbanda S, El-Sayed Y, Blumenfeld Y, Stevenson DK, Shaw GM, Wolfe ND, Quake SR.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9623-9628. doi: 10.1073/pnas.1707009114. Epub 2017 Aug 22.

4.

Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.

Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M, Kharbanda S, Raisner R, Haverty PM, Modrusan Z, Ly J, Choo E, Kaufman S, Beresini MH, Romero FA, Magnuson S, Gascoigne KE.

Cancer Res. 2017 Oct 15;77(20):5564-5575. doi: 10.1158/0008-5472.CAN-17-0314. Epub 2017 Aug 17.

PMID:
28819026
5.

Quantification of transplant-derived circulating cell-free DNA in absence of a donor genotype.

Sharon E, Shi H, Kharbanda S, Koh W, Martin LR, Khush KK, Valantine H, Pritchard JK, De Vlaminck I.

PLoS Comput Biol. 2017 Aug 3;13(8):e1005629. doi: 10.1371/journal.pcbi.1005629. eCollection 2017 Aug.

6.

Bone marrow oedema predicts bone collapse in paediatric and adolescent leukaemia patients with corticosteroid-induced osteonecrosis.

Theruvath AJ, Sukerkar PA, Bao S, Rosenberg J, Luna-Fineman S, Kharbanda S, Daldrup-Link HE.

Eur Radiol. 2018 Jan;28(1):410-417. doi: 10.1007/s00330-017-4961-2. Epub 2017 Jul 19.

PMID:
28726121
7.

A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for β-Thalassemia.

Chaudhury S, Ayas M, Rosen C, Ma M, Viqaruddin M, Parikh S, Kharbanda S, Chiang KY, Haight A, Bhatia M, Guilcher G, Thompson A, Shenoy S.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1695-1700. doi: 10.1016/j.bbmt.2017.06.004. Epub 2017 Jun 13.

PMID:
28627425
8.

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.

Lewis Phillips GD, Nishimura MC, Lacap JA, Kharbanda S, Mai E, Tien J, Malesky K, Williams SP, Marik J, Phillips HS.

Breast Cancer Res Treat. 2017 Aug;164(3):581-591. doi: 10.1007/s10549-017-4279-4. Epub 2017 May 10.

9.

Pericardial Effusion Following Hematopoietic Cell Transplantation in Children and Young Adults Is Associated with Increased Risk of Mortality.

Cox K, Punn R, Weiskopf E, Pinsky BA, Kharbanda S.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1165-1169. doi: 10.1016/j.bbmt.2017.03.028. Epub 2017 Apr 5.

PMID:
28390986
10.

Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system.

Shukla V, Dalela M, Vij M, Weichselbaum R, Kharbanda S, Ganguli M, Kufe D, Singh H.

Nanomedicine. 2017 Jul;13(5):1833-1839. doi: 10.1016/j.nano.2017.03.004. Epub 2017 Mar 23.

PMID:
28343015
11.

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.

Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, Kharbanda S, Wong KK, Kufe D.

Oncogene. 2017 Jul 13;36(28):4037-4046. doi: 10.1038/onc.2017.47. Epub 2017 Mar 13.

12.

Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.

Ahmad R, Alam M, Hasegawa M, Uchida Y, Al-Obaid O, Kharbanda S, Kufe D.

Mol Cancer. 2017 Feb 2;16(1):33. doi: 10.1186/s12943-017-0608-9.

13.

MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.

Tagde A, Rajabi H, Stroopinsky D, Gali R, Alam M, Bouillez A, Kharbanda S, Stone R, Avigan D, Kufe D.

Oncotarget. 2016 Jun 28;7(26):38974-38987. doi: 10.18632/oncotarget.9777.

14.

Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.

Crawford TD, Romero FA, Lai KW, Tsui V, Taylor AM, de Leon Boenig G, Noland CL, Murray J, Ly J, Choo EF, Hunsaker TL, Chan EW, Merchant M, Kharbanda S, Gascoigne KE, Kaufman S, Beresini MH, Liao J, Liu W, Chen KX, Chen Z, Conery AR, Côté A, Jayaram H, Jiang Y, Kiefer JR, Kleinheinz T, Li Y, Maher J, Pardo E, Poy F, Spillane KL, Wang F, Wang J, Wei X, Xu Z, Xu Z, Yen I, Zawadzke L, Zhu X, Bellon S, Cummings R, Cochran AG, Albrecht BK, Magnuson S.

J Med Chem. 2016 Dec 8;59(23):10549-10563. Epub 2016 Sep 28.

PMID:
27682507
15.

Invasive Fungal Disease in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant.

Aftandilian C, Weinberg K, Willert J, Kharbanda S, Porteus M, Maldonado Y, Agarwal R.

J Pediatr Hematol Oncol. 2016 Oct;38(7):574-580.

PMID:
27658021
16.

Predictive Value of Fecal Calprotectin in Pediatric Graft-Versus-Host Disease.

Wadhwani SI, Nakayuenyongsuk W, Shinn L, Chase P, Kharbanda S, Bass D, Park KT.

J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):e208-e209. No abstract available.

PMID:
27504814
17.

Custom ocular prosthesis in rehabilitation of a child operated for retinoblastoma.

Shah V, Yadav L, Singh M, Kharbanda S.

Natl J Maxillofac Surg. 2015 Jul-Dec;6(2):232-6. doi: 10.4103/0975-5950.183871.

18.

Applications of botulinum toxin in dentistry: A comprehensive review.

Srivastava S, Kharbanda S, Pal US, Shah V.

Natl J Maxillofac Surg. 2015 Jul-Dec;6(2):152-9. doi: 10.4103/0975-5950.183860. Review.

19.

MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.

Hiraki M, Suzuki Y, Alam M, Hinohara K, Hasegawa M, Jin C, Kharbanda S, Kufe D.

Sci Rep. 2016 May 24;6:26643. doi: 10.1038/srep26643.

20.

pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice.

Dalela M, Shrivastav TG, Kharbanda S, Singh H.

ACS Appl Mater Interfaces. 2015 Dec 9;7(48):26530-48. doi: 10.1021/acsami.5b07764. Epub 2015 Nov 23.

PMID:
26528585
21.

Prevalence of quadriceps muscle weakness in patients with COPD and its association with disease severity.

Kharbanda S, Ramakrishna A, Krishnan S.

Int J Chron Obstruct Pulmon Dis. 2015 Sep 1;10:1727-35. doi: 10.2147/COPD.S87791. eCollection 2015.

22.

Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.

Raina D, Agarwal P, Lee J, Bharti A, McKnight CJ, Sharma P, Kharbanda S, Kufe D.

PLoS One. 2015 Aug 12;10(8):e0135156. doi: 10.1371/journal.pone.0135156. eCollection 2015.

23.

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C.

J Clin Oncol. 2015 Sep 1;33(25):2735-44. doi: 10.1200/JCO.2015.61.5005. Epub 2015 Jun 29. Erratum in: J Clin Oncol. 2016 Sep 1;34(25):3113.

24.

Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.

Hasegawa M, Sinha RK, Kumar M, Alam M, Yin L, Raina D, Kharbanda A, Panchamoorthy G, Gupta D, Singh H, Kharbanda S, Kufe D.

Clin Cancer Res. 2015 May 15;21(10):2338-47. doi: 10.1158/1078-0432.CCR-14-3000. Epub 2015 Feb 23.

25.

A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor.

Mahadeo KM, Weinberg KI, Abdel-Azim H, Miklos DB, Killen R, Kohn D, Crooks GM, Shah AJ, Kharbanda S, Agarwal R, Kapoor N.

Biol Blood Marrow Transplant. 2015 Mar;21(3):440-4. doi: 10.1016/j.bbmt.2014.11.005. Epub 2014 Nov 13.

26.

Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.

Garfin PM, Link MP, Donaldson SS, Advani RH, Luna-Fineman S, Kharbanda S, Porteus M, Weinberg KI, Agarwal-Hashmi R.

Biol Blood Marrow Transplant. 2015 Feb;21(2):326-34. doi: 10.1016/j.bbmt.2014.10.020. Epub 2014 Oct 29.

27.

A pediatric case of T-cell prolymphocytic leukemia.

Mitton B, Coutre S, Willert J, Schlis K, Porteus M, Kharbanda S, Agarwal-Hashmi R.

Pediatr Blood Cancer. 2015 Jun;62(6):1061-2. doi: 10.1002/pbc.25336. Epub 2014 Nov 21.

PMID:
25417638
28.

Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9.

Kumar M, Singh G, Sharma S, Gupta D, Bansal V, Arora V, Bhat M, Srivastava SK, Sapra S, Kharbanda S, Dinda AK, Singh H.

Nanoscale. 2014 Nov 6;6(23):14473-83. doi: 10.1039/c4nr04504a.

PMID:
25340469
29.

Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.

Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, Forrest WF, Kwong M, Hedehus M, Hatzivassiliou G, Friedman LS, Phillips HS.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14217-22. doi: 10.1073/pnas.1409653111. Epub 2014 Sep 15.

30.

Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9.

Kumar M, Gupta D, Singh G, Sharma S, Bhat M, Prashant CK, Dinda AK, Kharbanda S, Kufe D, Singh H.

Cancer Res. 2014 Jun 15;74(12):3271-81. doi: 10.1158/0008-5472.CAN-13-2015. Epub 2014 Apr 16.

31.

Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.

Kharbanda S, Smith AR, Hutchinson SK, McKenna DH, Ball JB, Lamb LS Jr, Agarwal R, Weinberg KI, Wagner JE Jr.

Biol Blood Marrow Transplant. 2014 Apr;20(4):581-6. doi: 10.1016/j.bbmt.2013.12.564. Epub 2013 Dec 24.

32.

MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Liu S, Yin L, Stroopinsky D, Rajabi H, Puissant A, Stegmaier K, Avigan D, Kharbanda S, Kufe D, Stone R.

Blood. 2014 Jan 30;123(5):734-42. doi: 10.1182/blood-2013-04-493858. Epub 2013 Nov 26.

33.

Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.

Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D.

Oncogene. 2014 Jun 26;33(26):3422-31. doi: 10.1038/onc.2013.308. Epub 2013 Aug 5.

34.

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL, Frank DA.

Genes Cancer. 2012 Jul;3(7-8):503-11. doi: 10.1177/1947601912466555.

35.

Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.

Uchida Y, Raina D, Kharbanda S, Kufe D.

Cancer Biol Ther. 2013 Feb;14(2):127-34. doi: 10.4161/cbt.22634. Epub 2012 Oct 31.

36.

Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.

Salphati L, Heffron TP, Alicke B, Nishimura M, Barck K, Carano RA, Cheong J, Edgar KA, Greve J, Kharbanda S, Koeppen H, Lau S, Lee LB, Pang J, Plise EG, Pokorny JL, Reslan HB, Sarkaria JN, Wallin JJ, Zhang X, Gould SE, Olivero AG, Phillips HS.

Clin Cancer Res. 2012 Nov 15;18(22):6239-48. doi: 10.1158/1078-0432.CCR-12-0720. Epub 2012 Sep 19.

37.

Cellular interaction of folic acid conjugated superparamagnetic iron oxide nanoparticles and its use as contrast agent for targeted magnetic imaging of tumor cells.

Kumar M, Singh G, Arora V, Mewar S, Sharma U, Jagannathan NR, Sapra S, Dinda AK, Kharbanda S, Singh H.

Int J Nanomedicine. 2012;7:3503-16. doi: 10.2147/IJN.S32694. Epub 2012 Jul 6.

38.

MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.

Rajabi H, Ahmad R, Jin C, Joshi MD, Guha M, Alam M, Kharbanda S, Kufe D.

Prostate. 2012 Nov;72(15):1659-68. doi: 10.1002/pros.22519. Epub 2012 Apr 2.

39.

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55. doi: 10.3174/ajnr.A2950. Epub 2012 Feb 9.

40.

Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival.

Pope WB, Mirsadraei L, Lai A, Eskin A, Qiao J, Kim HJ, Ellingson B, Nghiemphu PL, Kharbanda S, Soriano RH, Nelson SF, Yong W, Phillips HS, Cloughesy TF.

AJNR Am J Neuroradiol. 2012 Jun;33(6):1059-64. doi: 10.3174/ajnr.A2917. Epub 2012 Jan 19.

41.

Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells.

Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S, Kufe D.

Int J Oncol. 2012 May;40(5):1643-9. doi: 10.3892/ijo.2011.1308. Epub 2011 Dec 20.

42.

AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD.

Yang X, Liu S, Kharbanda S, Stone RM.

Leuk Res. 2012 Feb;36(2):205-11. doi: 10.1016/j.leukres.2011.09.006. Epub 2011 Dec 3.

43.

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS.

J Clin Oncol. 2011 Dec 1;29(34):4482-90. doi: 10.1200/JCO.2010.33.8715. Epub 2011 Oct 24.

44.

MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells.

Yin L, Wu Z, Avigan D, Rosenblatt J, Stone R, Kharbanda S, Kufe D.

Blood. 2011 May 5;117(18):4863-70. doi: 10.1182/blood-2010-10-296632. Epub 2011 Mar 21.

45.

Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.

Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D.

Mol Cancer Ther. 2011 May;10(5):806-16. doi: 10.1158/1535-7163.MCT-10-1050. Epub 2011 Mar 18.

46.

Gene expression analysis in radiotherapy patients and C57BL/6 mice as a measure of exposure to ionizing radiation.

Filiano AN, Fathallah-Shaykh HM, Fiveash J, Gage J, Cantor A, Kharbanda S, Johnson MR.

Radiat Res. 2011 Jul;176(1):49-61. doi: 10.1667/RR2419.1. Epub 2011 Mar 1.

PMID:
21361780
47.

MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop.

Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B, Kawano T, Kharbanda S, Kufe D.

Sci Signal. 2011 Feb 15;4(160):ra9. doi: 10.1126/scisignal.2001426.

48.

A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target.

Schulte A, Günther HS, Phillips HS, Kemming D, Martens T, Kharbanda S, Soriano RH, Modrusan Z, Zapf S, Westphal M, Lamszus K.

Glia. 2011 Apr;59(4):590-602. doi: 10.1002/glia.21127. Epub 2011 Feb 3.

PMID:
21294158
49.

MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation.

Huang L, Liao X, Beckett M, Li Y, Khanna KK, Wang Z, Kharbanda S, Weichselbaum R, Kufe D.

Genes Cancer. 2010 Mar;1(3):239-250.

50.

Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.

Yin L, Ahmad R, Kosugi M, Kawano T, Avigan D, Stone R, Kharbanda S, Kufe D.

Cancer Biol Ther. 2010 Sep 1;10(5):483-91. Epub 2010 Sep 4.

Supplemental Content

Loading ...
Support Center